🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Dermatomyositis

Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES NCT07265999n/a1 site📍 Pointe-à-Pitre Centre Hospitalier Universitaire de la Guadeloupe Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases NCT07558850NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: anti-CD19/BCMA-UCAR-T cells Adult and Juvenile Myositis NCT00017914n/a4 sites📍 Atlanta📍 Bethesda📍 Research Triangle Park National Institute of Environmental Health Sciences (NIEHS) Rheumatology Diet Study NCT06339957n/a1 site📍 Orlando University of Central Florida Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) NCT06686524Phase 11 site📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: Anti-CD19 UCAR-T cells Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042Phase 1, Phase 21 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: CAR T cell Panniculitis in Dermatomyositis NCT07345949n/a1 site📍 Strasbourg University Hospital, Strasbourg, France Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases NCT07184450Phase 11 site📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: BCMA/CD70-targetd CAR-T MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) NCT07374107n/a1 site📍 New Orleans Myositis International Health & Research Collaborative Alli… · Tests: No intervention - qualitative and mixed methods investigations Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) NCT07160205Phase 2, Phase 32 sites📍 Gainesville📍 Miami Restem, LLC. · Tests: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells) Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases NCT06599411n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Sampling, Sampling Optimizing Treatment on Idiopathic Inflammatory Myopathies NCT03092180n/a1 site📍 São Paulo University of Sao Paulo · Tests: Intravenous Infusion Environmental Risk Factors for the Anti-synthetase Syndrome NCT01276470n/a8 sites📍 Miami📍 Baltimore📍 Bethesda National Institute of Environmental Health Sciences (NIEHS) A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies NCT06698796Phase 326 sites📍 Glendale📍 Frisco📍 Houston Pfizer · Tests: Dazukibart Rheumatology Patient Registry and Biorepository NCT04402086n/a1 site📍 New Haven Yale University A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) NCT06455449Phase 3237 sites📍 Phoenix📍 Irvine📍 Aurora AstraZeneca · Tests: Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label) Baricitinib in Patients With Relapsing or naïve Dermatomyositis NCT04972760Phase 31 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Baricitinib, Placebo BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy NCT07715136Phase 11 site📍 Chengdu iCell Gene Therapeutics · Tests: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease NCT06203249n/a1 site📍 Beijing Chinese PLA General Hospital A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases NCT07115745Phase 128 sites📍 Boston📍 Durham📍 Camperdown Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis NCT06569472Phase 11 site📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CD19-targetd CAR-T A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] NCT05895786Phase 3138 sites📍 Glendale📍 Phoenix📍 Phoenix Pfizer · Tests: PF-06823859, Placebo FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) NCT07111065Phase 21 site📍 Bethesda National Institute of Environmental Health Sciences (NIEHS) · Tests: FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation NCT07037472NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: Multi-modal photoacoustic/ultrasonic (PA/US) imaging system, Drug treatment Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial NCT06919380Phase 11 site📍 Guangzhou Li Shiyue · Tests: MSC-exos Nebulization Therapy Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty NCT07138898Phase 21 site📍 New York NYU Langone Health · Tests: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases NCT06387654n/a1 site📍 Toulouse University Hospital, Toulouse · Tests: Blood sampling, Remainders of samples taken as part of the treatment Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) NCT02945345n/a1 site📍 Philadelphia University of Pennsylvania CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease NCT06347718Phase 1, Phase 21 site📍 Erlangen Miltenyi Biomedicine GmbH · Tests: anti-CD19 CAR T cell therapy Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis NCT06298019Phase 12 sites📍 Palo Alto📍 Stanford Stanford University · Tests: KYV-101
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy